Trailing-twelve-month (TTM) revenue is $14.01 Billion with a year-over-year growth of +6.45%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $3,420,227,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-10-29 |
| Q4 FY2025Period ended 2025-12-31 | $3,619,787,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-11 |
| Q1 FY2026Period ended 2026-03-31 | $3,415,548,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-05 |
| Q2 FY2026Period ended 2026-06-30 | $3,554,084,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-04 |
| TTM revenue | $14,009,646,000 |
Current P/S: $11,655,510,000 market capitalization ÷ $14,009,646,000 TTM revenue = 0.83x.
Market capitalization source: FMP quote. Quote observed 2026-09-11T20:00:03.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $3.55B.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-09-12T00:15:29.230Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-10.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Other Segments | $1.1B | $1.0B | $1.1B | $1.3B | N/A | N/A |
| U S Dialysis And Related Lab Services | $10.7B | $10.7B |
$14.01B
$14.01 Billion
+6.45%
vs. $13.16B a year ago (TTM)
+3.91%
5 Year compound annual growth rate
1 Year
+6.45%
3 Year
+6.07%
5 Year
+3.91%
10 Year
(0.25%)
15 Year
+5.13%
20 Year
+6.35%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $13.64B | +$827.52M | +6.46% |
| 2024 | $12.82B | +$675.40M | +5.56% |
| 2023 | $12.14B | +$530.25M | +4.57% |
| 2022 | $11.61B | ($8.90M) | (0.08%) |
| 2021 | $11.62B | +$68.19M | +0.59% |
| 2020 |
TTM Growth
+6.45%
3-Year CAGR
+6.07%
5-Year CAGR
+3.91%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-09-12T00:15:29.230Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-10.
| $10.9B |
| $11.3B |
| $11.7B |
| $11.55B |
| +$162.13M |
| +1.42% |
| 2019 | $11.39B | ($16.37M) | (0.14%) |
| 2018 | $11.40B | +$528.22M | +4.86% |
| 2017 | $10.88B | ($3.87B) | (26.24%) |
| 2016 | $14.75B | +$963.27M | +6.99% |
